• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病肝硬化患者的衰弱情况:与酒精性肝硬化的比较、风险模式以及对预后的影响。

Frailty in Nonalcoholic Fatty Liver Cirrhosis: A Comparison with Alcoholic Cirrhosis, Risk Patterns, and Impact on Prognosis.

机构信息

Department of Hepatology, Gastroenterology, and Transplantation (HEGITO), 2 Department of Medicine, Slovak Medical University, FD Roosevelt Faculty Hospital, Nám. L. Svobodu 1, Banska Bystrica 97517, Slovakia.

Gastroenterology and Hepatology Subdivision, 5 Department of Medicine, Comenius University Faculty of Medicine, University Hospital Bratislava, Ruzinovska 6, Bratislava 82606, Slovakia.

出版信息

Can J Gastroenterol Hepatol. 2021 May 21;2021:5576531. doi: 10.1155/2021/5576531. eCollection 2021.

DOI:10.1155/2021/5576531
PMID:34095016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8163557/
Abstract

BACKGROUND

Physical frailty increases susceptibility to stressors and predicts adverse outcomes of cirrhosis. Data on disease course in different etiologies are scarce, so we aimed to compare the prevalence and risk factors of frailty and its impact on prognosis in nonalcoholic fatty liver (NAFLD) and alcoholic (ALD) cirrhosis. . Cirrhosis registry RH7 operates since 2014 and includes hospitalized patients with decompensated cirrhosis, pre-LT evaluation, or curable hepatocellular carcinoma (HCC). From the RH7, we identified 280 ALD and 105 NAFLD patients with at least 6 months of follow-up.

RESULTS

Patients with NAFLD compared with ALD were older and had a higher proportion of females, higher body mass index (BMI) and mid-arm circumference (MAC), lower MELD score, CRP, and lower proportion of refractory ascites. The liver frailty index did not differ, and the prevalence of HCC was higher (17.1 vs. 6.8%, =0.002). Age, sex, serum albumin, and C-reactive protein (CRP) were independent predictors of frailty. In NAFLD, frailty was also associated with BMI and MAC and in ALD, with the MELD score. The Cox model adjusted for age, sex, MELD, CRP, HCC, and LFI showed that NAFLD patients had higher all-cause mortality (HR = 1.88 95% CI 1.32-2.67, < 0.001) and were more sensitive to the increase in LFI (HR = 1.51, 95% CI 1.05-2.2).

CONCLUSION

Patients with NAFLD cirrhosis had a comparable prevalence of frailty compared to ALD. Although prognostic indices showed less advanced disease, NAFLD patients were more sensitive to frailty, which reflected their higher overall disease burden and led to higher all-cause mortality.

摘要

背景

身体虚弱会增加对压力源的易感性,并预测肝硬化的不良后果。关于不同病因的疾病过程的数据很少,因此我们旨在比较非酒精性脂肪性肝病 (NAFLD) 和酒精性 (ALD) 肝硬化中虚弱的患病率和危险因素及其对预后的影响。RH7 肝硬化登记处自 2014 年起运作,包括失代偿性肝硬化、LT 前评估或可治愈的肝细胞癌 (HCC) 的住院患者。我们从 RH7 中确定了 280 名 ALD 和 105 名 NAFLD 患者,他们的随访时间至少为 6 个月。

结果

与 ALD 患者相比,NAFLD 患者年龄较大,女性比例较高,体重指数 (BMI) 和上臂中部周长 (MAC) 较高,MELD 评分、C 反应蛋白 (CRP) 较低,难治性腹水的比例较低。肝脏虚弱指数没有差异,肝癌的患病率较高(17.1%比 6.8%,=0.002)。年龄、性别、血清白蛋白和 C 反应蛋白 (CRP) 是虚弱的独立预测因素。在 NAFLD 中,虚弱也与 BMI 和 MAC 相关,而在 ALD 中,与 MELD 评分相关。调整年龄、性别、MELD、CRP、HCC 和 LFI 的 Cox 模型显示,NAFLD 患者的全因死亡率更高(HR=1.88,95%CI 1.32-2.67,<0.001),对 LFI 的增加更敏感(HR=1.51,95%CI 1.05-2.2)。

结论

与 ALD 相比,NAFLD 肝硬化患者虚弱的患病率相当。尽管预后指数显示疾病进展程度较低,但 NAFLD 患者对虚弱更为敏感,这反映了他们更高的整体疾病负担,并导致全因死亡率更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2350/8163557/4d8e1e5508f9/CJGH2021-5576531.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2350/8163557/6edb33a8a0cd/CJGH2021-5576531.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2350/8163557/6b7ee8064c17/CJGH2021-5576531.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2350/8163557/4d8e1e5508f9/CJGH2021-5576531.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2350/8163557/6edb33a8a0cd/CJGH2021-5576531.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2350/8163557/6b7ee8064c17/CJGH2021-5576531.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2350/8163557/4d8e1e5508f9/CJGH2021-5576531.003.jpg

相似文献

1
Frailty in Nonalcoholic Fatty Liver Cirrhosis: A Comparison with Alcoholic Cirrhosis, Risk Patterns, and Impact on Prognosis.非酒精性脂肪性肝病肝硬化患者的衰弱情况:与酒精性肝硬化的比较、风险模式以及对预后的影响。
Can J Gastroenterol Hepatol. 2021 May 21;2021:5576531. doi: 10.1155/2021/5576531. eCollection 2021.
2
Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.用于风险分层的酒精或非酒精性脂肪性肝病相关肝硬化患者肝细胞癌风险的预测模型。
J Hepatol. 2019 Sep;71(3):523-533. doi: 10.1016/j.jhep.2019.05.008. Epub 2019 May 28.
3
Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.一项观察性研究表明,在肝硬化患者中,酒精性肝病的预后比丙型肝炎病毒感染和非酒精性脂肪性肝病更差。
PLoS One. 2017 Oct 27;12(10):e0186715. doi: 10.1371/journal.pone.0186715. eCollection 2017.
4
Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.瘦型与非瘦型非酒精性脂肪性肝病的临床和代谢特征比较。
Indian J Gastroenterol. 2021 Aug;40(4):380-388. doi: 10.1007/s12664-021-01184-6. Epub 2021 Jul 2.
5
Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey.日本非酒精性脂肪性肝病和酒精性肝病患者的肝细胞癌:多中心调查。
J Gastroenterol. 2016 Jun;51(6):586-96. doi: 10.1007/s00535-015-1129-1. Epub 2015 Oct 11.
6
Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.酒精性肝病在晚期出现,与非酒精性脂肪性肝病相比进展更快。
Ann Hepatol. 2016 Mar-Apr;15(2):183-9. doi: 10.5604/16652681.1193707.
7
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.2004 年至 2009 年美国非酒精性脂肪性肝病(NAFLD)与肝细胞癌(HCC)的相关性。
Hepatology. 2015 Dec;62(6):1723-30. doi: 10.1002/hep.28123. Epub 2015 Oct 24.
8
Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.在四个欧洲队列中对诊断为非酒精性脂肪性肝病的成年人进行的真实世界研究:肝硬化和肝细胞癌诊断的风险和临床预测因子。
BMC Med. 2019 May 20;17(1):95. doi: 10.1186/s12916-019-1321-x.
9
Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者肝细胞癌的临床特征和预后。
Can J Gastroenterol Hepatol. 2020 Jun 3;2020:4873875. doi: 10.1155/2020/4873875. eCollection 2020.
10
Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.乙型肝炎核心抗体阳性与非酒精性脂肪性肝病患者的肝硬化和肝细胞癌相关。
Am J Gastroenterol. 2020 Jun;115(6):867-875. doi: 10.14309/ajg.0000000000000588.

引用本文的文献

1
Frailty as a determinant of liver transplant outcomes: A call for integrative strategies.衰弱作为肝移植结局的一个决定因素:呼吁采取综合策略。
World J Transplant. 2025 Sep 18;15(3):104500. doi: 10.5500/wjt.v15.i3.104500.
2
Does the change in Liver Frailty Index over the first week of hospitalisation predict mortality in patients with acute-on-chronic liver failure? A prospective cohort study from a Slovak liver centre.住院第一周内肝脏脆弱指数的变化能否预测慢性肝衰竭急性发作患者的死亡率?一项来自斯洛伐克肝脏中心的前瞻性队列研究。
BMJ Open. 2025 May 28;15(5):e100171. doi: 10.1136/bmjopen-2025-100171.
3
Role of Nutrition in the Management of Chronic Liver Disease.

本文引用的文献

1
Applicability and prognostic value of frailty assessment tools among hospitalized patients with advanced chronic liver disease.住院的晚期慢性肝病患者中衰弱评估工具的适用性和预后价值。
Croat Med J. 2021 Feb 28;62(1):8-16. doi: 10.3325/cmj.2021.62.8.
2
Adherence to Oral Nutritional Supplements After Being Discharged from the Hospital is Low but Improves Outcome in Patients with Advanced Chronic Liver Disease.晚期慢性肝病患者出院后口服营养补充剂的依从性较低,但可改善预后。
Patient Prefer Adherence. 2021 Jan 5;14:2559-2572. doi: 10.2147/PPA.S283034. eCollection 2020.
3
Pre-transplant Sarcopenic Obesity Worsens the Survival After Liver Transplantation: A Meta-Analysis and a Systematic Review.
营养在慢性肝病管理中的作用。
Gastro Hep Adv. 2025 Jan 2;4(5):100613. doi: 10.1016/j.gastha.2024.100613. eCollection 2025.
4
A systematic review of the relationship between body composition including muscle, fat, bone, and body water and frailty in Asian residents.一项关于亚洲居民身体成分(包括肌肉、脂肪、骨骼和身体水分)与衰弱之间关系的系统评价。
Nagoya J Med Sci. 2025 Feb;87(1):1-21. doi: 10.18999/nagjms.87.1.1.
5
Hepatic venous pressure gradient in patients with (compensated and decompensated) advanced chronic liver disease - A comparison of metabolic dysfunction-associated steatotic liver disease with alcohol-associated liver disease: A retrospective view.(代偿期和失代偿期)晚期慢性肝病患者的肝静脉压力梯度——代谢功能障碍相关脂肪性肝病与酒精性肝病的比较:一项回顾性研究。
PLoS One. 2025 Mar 5;20(3):e0317287. doi: 10.1371/journal.pone.0317287. eCollection 2025.
6
The impact of dietary fiber on colorectal cancer patients based on machine learning.基于机器学习的膳食纤维对结直肠癌患者的影响
Front Nutr. 2025 Jan 24;12:1508562. doi: 10.3389/fnut.2025.1508562. eCollection 2025.
7
Prospective study on time-to-tertiary care in alcohol-associated hepatitis: space-time coordinates as prognostic tool and therapeutic target.酒精性肝炎三级医疗时间的前瞻性研究:时空坐标作为预后工具和治疗靶点。
Alcohol Alcohol. 2025 Jan 19;60(2). doi: 10.1093/alcalc/agae092.
8
3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation.利用粪便微生物群移植在严重酒精性肝炎治疗中进行以精准医学为导向的创新。
EPMA J. 2024 Oct 31;15(4):677-692. doi: 10.1007/s13167-024-00381-5. eCollection 2024 Dec.
9
Assessment of intestinal inflammation via fecal calprotectin for early prediction of adverse outcomes in advanced chronic liver disease.通过粪便钙卫蛋白评估肠道炎症以早期预测晚期慢性肝病的不良结局
United European Gastroenterol J. 2025 Apr;13(3):305-316. doi: 10.1002/ueg2.12633. Epub 2024 Jul 19.
10
Etiology-Specific Effects of Impaired Functional Status on Liver Transplant Outcomes.功能状态受损对肝移植结局的病因特异性影响。
Dig Dis Sci. 2024 Sep;69(9):3513-3553. doi: 10.1007/s10620-024-08522-6. Epub 2024 Jul 16.
肝移植前肌少症性肥胖会降低肝移植后的生存率:一项荟萃分析和系统评价
Front Med (Lausanne). 2020 Dec 16;7:599434. doi: 10.3389/fmed.2020.599434. eCollection 2020.
4
Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?非酒精性脂肪性肝病与肌肉减少症:我们处于何种境地?
Can J Gastroenterol Hepatol. 2020 Oct 31;2020:8859719. doi: 10.1155/2020/8859719. eCollection 2020.
5
What's in a name? Renaming 'NAFLD' to 'MAFLD'.名字里有什么?将“非酒精性脂肪性肝病”重新命名为“代谢功能障碍相关脂肪性肝病” 。 (备注:MAFLD全称为Metabolic Dysfunction-Associated Fatty Liver Disease ,直译为代谢功能障碍相关脂肪性肝病 ,是对NAFLD(Non-alcoholic Fatty Liver Disease,非酒精性脂肪性肝病)的重新命名 。这里如果仅按字面意思翻译,可能不太能理解其背景含义,补充了备注供你参考。)
Liver Int. 2020 Jun;40(6):1254-1261. doi: 10.1111/liv.14478. Epub 2020 Apr 28.
6
Changes in frailty are associated with waitlist mortality in patients with cirrhosis.衰弱的变化与肝硬化患者等待移植名单期间的死亡率相关。
J Hepatol. 2020 Sep;73(3):575-581. doi: 10.1016/j.jhep.2020.03.029. Epub 2020 Mar 30.
7
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.2012 年至 2017 年全球慢性肝病负担的变化:非酒精性脂肪性肝病的影响日益增加。
Hepatology. 2020 Nov;72(5):1605-1616. doi: 10.1002/hep.31173. Epub 2020 Oct 27.
8
Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease.体力活动不足和久坐行为是非酒精性脂肪性肝病的独立预测因素。
Hepatology. 2020 Nov;72(5):1556-1568. doi: 10.1002/hep.31158. Epub 2020 Oct 22.
9
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.2017 年全球疾病负担研究:1990-2017 年 195 个国家和地区按病因划分的肝硬化全球、区域和国家负担:系统分析。
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266. doi: 10.1016/S2468-1253(19)30349-8. Epub 2020 Jan 22.
10
Assessment of Malnutrition, Sarcopenia and Frailty in Patients with Cirrhosis: Which Tools Should We Use in Clinical Practice?肝硬化患者的营养评估、肌肉减少症和衰弱:临床实践中我们应该使用哪些工具?
Nutrients. 2020 Jan 9;12(1):186. doi: 10.3390/nu12010186.